Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In previous experiments, replacing the 10-mg/kg of body weight daily dose of rifampin with 7.5 to 10 mg/kg of rifapentine in combinations containing isoniazid and pyrazinamide reduced the duration of treatment needed to cure tuberculosis in BALB/c mice by approximately 50% due to rifapentine's more potent activity and greater drug exposures obtained. In the present study, we performed dose-ranging comparisons of the bactericidal and sterilizing activities of rifampin and rifapentine, alone and in combination with isoniazid and pyrazinamide with or without ethambutol, in BALB/c mice and in C3HeB/FeJ mice, which develop necrotic lung granulomas after infection with Mycobacterium tuberculosis . Each rifamycin demonstrated a significant increase in sterilizing activity with increasing dose. Rifapentine was roughly 4 times more potent in both mouse strains. These results reinforce the rationale for ongoing clinical trials to ascertain the highest well-tolerated doses of rifampin and rifapentine. This study also provides an important benchmark for the efficacy of the first-line regimen in C3HeB/FeJ mice, a strain in which the lung lesions observed after M. tuberculosis infection may better represent the pathology of human tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627 · cited 1×
“The similar efficacies of the first-line regimen in both strains and the selection of clinically relevant RIF-resistant mutants (14, 48) with monotherapy provide an important benchmark for future studies evaluating the potential value of C3HeB/FeJ mice as a model for evaluation of experimental chemotherapy for TB.”
Background
Cited by
Boeree, M. J., Heinrich, N., Aarnoutse, R., Diacon, A. H., Dawson, R., Rehal, S., Kibiki, G. S., Churchyard, G., Sanne, I., Ntinginya, N. E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30274-2 · Cited by 379
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses
Lenaerts, A., Barry, C. E., & Dartois, V. (2015) · Immunological Reviews · doi:10.1111/imr.12252 · Cited by 362
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Boeree, M. J., Diacon, A. H., Dawson, R., Narunsky, K., du Bois, J., Venter, A., Phillips, P. P. J., Gillespie, S. H., McHugh, T. D., Hoelscher, M., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201407-1264oc · Cited by 309
Rifat, D., Chen, L., Kreiswirth, B. N., & Nuermberger, E. L. (2021) · mBio · doi:10.1128/mbio.01049-21 · Cited by 76
Self-citationPeloquin, C. A., Dorman, S. E., Vernon, A., Battista Migliori, G., & Nahid, P. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw679 · Cited by 6
Self-citation
Metadata
- Authors
- Rosenthal, I. M., Tasneen, R., Peloquin, C. A., Zhang, M., Almeida, D., Mdluli, K. E., Karakousis, P. C., Grosset, J. H., & Nuermberger, E. L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-08
- Volume
- 56
- Issue
- 8
- Pages
- 4331-4340
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2155898568
- Cited by
- 149
- References
- 1
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis. https://app.cochat.ai/papers/10.1128/aac.00912-12
- The paper
- Rosenthal, I. M., Tasneen, R., Peloquin, C. A., Zhang, M., Almeida, D., Mdluli, K. E., Karakousis, P. C., Grosset, J. H., & Nuermberger, E. L. (2012). Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00912-12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.